The FDA approved the drug for Barth syndrome despite findings by its data reviewers that the treatment, while safe, was no ...

MoonLake Immunotherapeutics’ stock has taken a pummeling after the biotech blamed an unexpectedly high placebo response rate for its much-hyped inflammatory disease prospect missing the key goal of ...

N. Gopalakrishna Iyer, MBBS, PhD, noting that the researchers were “quite surprised” by the overall survival achieved in the control arm, given the real-world setting of the trial.

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept ...

FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, while safe, ...